ReviewAdvances in experimental medicine and biology2026
Cognitive Deficits in Schizophrenia: Brain Deorganization and Neurorehabilitation.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a complex psychiatric disorder that significantly affects individuals and society. Its etiology and pathophysiology remain unclear, in part due to its heterogeneity. Although the neurobiological background is not fully understood, schizophrenia is considered a polygenic disorder influenced by multiple genes. Current hypotheses, such as the N-methyl-D-aspartate (NMDA) hypothesis, and the role of glial cells are under investigation. The disease manifests through positive, negative, and cognitive symptoms, having an impact on emotion, perception, and behavior. In particular, cognitive decline affects two domains: neurocognition (verbal memory, fluency, processing speed, working memory, visual learning, attention, reasoning, and problem-solving) and social cognition. Although pharmaceutical treatments aim to alleviate clinical symptoms, recent studies indicate that neurorehabilitation and cognitive training can improve cognitive and clinical outcomes by modifying the neurobiological framework. Cognitive therapies, like cognitive remediation therapy, RehaCom, and cognitive behavioral training, are becoming prominent. Neuroimaging studies suggest that these therapies can reorganize brain structure, thereby enhancing cognitive functions and improving daily and social life.
Indexed as
Identifiers
41273545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.